Gemtesa 75 mg can cause several side effects, with urinary tract infections (UTIs) being the most common. Other frequently reported side effects include difficulty urinating, pain during urination, and constipation.
What are the most common side effects of Gemtesa?
The most frequently observed side effects in clinical studies for Gemtesa 75 mg were urinary tract infections (UTIs), occurring in approximately 10.4% of patients. Difficulty urinating was reported in 5.7% of patients, pain during urination in 5.4%, and constipation in 4.1% [1].
Are there any serious side effects to be aware of with Gemtesa?
While less common, Gemtesa can cause serious side effects. These include urinary retention, which is the inability to urinate, and hypersensitivity reactions. Patients experiencing symptoms like swelling of the face, lips, tongue, or throat, difficulty breathing, or rash should seek immediate medical attention [1].
What happens if a patient develops urinary retention while taking Gemtesa?
Urinary retention is a serious side effect that requires prompt medical evaluation. If a patient is unable to urinate, they should stop taking Gemtesa and contact their healthcare provider immediately [1].
How does Gemtesa's side effect profile compare to other overactive bladder medications?
Different medications for overactive bladder have varying side effect profiles. For instance, antimuscarinic drugs, another class of OAB medication, commonly cause dry mouth, constipation, and blurred vision. Gemtesa, a beta-3 adrenergic agonist, tends to have a lower incidence of these specific anticholinergic side effects, with dry mouth being reported in fewer than 1% of patients in clinical trials [1][2].
What patient concerns are associated with Gemtesa's side effects?
Patient concerns often revolve around the management of common side effects like UTIs and constipation. The potential for urinary retention, though rare, is also a significant concern for patients starting this medication [1].
When does the patent for Gemtesa expire?
The patent exclusivity for Gemtesa (vibegron) is a complex area. While the primary patent for the compound itself may have a specific expiration date, additional patents related to formulations, methods of use, and manufacturing processes can extend market protection. Information on specific patent expiry dates can be found on resources like DrugPatentWatch.com [3].
Who manufactures Gemtesa?
Gemtesa is manufactured by Urovant Sciences [1].
What clinical data supports the safety and efficacy of Gemtesa 75 mg?
The safety and efficacy of Gemtesa 75 mg were evaluated in several clinical trials. The pivotal EMPOWR studies demonstrated that Gemtesa 75 mg was effective in reducing urinary urgency, frequency, and incontinence episodes in women with overactive bladder. The common side effects observed in these trials, such as UTIs and constipation, were generally mild to moderate in severity [1].
Are there alternatives to Gemtesa for treating overactive bladder?
Yes, several alternative treatments are available for overactive bladder. These include behavioral therapies, other oral medications (such as antimuscarinics and other beta-3 adrenergic agonists), and injectable treatments. Medical providers tailor treatment plans based on individual patient needs and responses [2].
---
1. Urovant Sciences. Gemtesa (vibegron) Prescribing Information.
2. National Institute of Diabetes and Digestive and Kidney Diseases. Overactive Bladder.
3. DrugPatentWatch. Vibegron Patents.